Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 2/3 1

Status

Not yet recruiting 3Recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Colorectal Neoplasms 442Stomach Neoplasms 290Rectal Neoplasms 266Colonic Neoplasms 191Pancreatic Neoplasms 175Neoplasm Metastasis 110Esophageal Neoplasms 87Neoplasms 68Carcinoma, Hepatocellular 59Adenocarcinoma Of Esophagus 47Adenocarcinoma 46Lymphoma, Large B-Cell, Diffuse 44Cholangiocarcinoma 44Carcinoma, Non-Small-Cell Lung 41Biliary Tract Neoplasms 37Gallbladder Neoplasms 30Gastrointestinal Neoplasms 29Recurrence 25Liver Neoplasms 24Ovarian Neoplasms 23Esophageal Squamous Cell Carcinoma 23Breast Neoplasms 22Peritoneal Neoplasms 17Bile Duct Neoplasms 17Unspecified Adult Solid Tumor, Protocol Specific 16Parkinson Disease 4, Autosomal Dominant Lewy Body 14Locally Advanced Rectal Cancer 13Head and Neck Neoplasms 13Lung Neoplasms 12Lymphoma, Non-Hodgkin 11

Interventions

Trastuzumab 5Oxaliplatin 4Capecitabine 3tislelizumab 2disitamab vedotin 2Tegafur 2Fluorouracil 2Cisplatin 2tucatinib 1trastuzumab deruxtecan 1pembrolizumab 1S 1 (combination) 1Ramucirumab 1Paclitaxel 1HMPL-013 1Drug Therapy 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × HER2-positive Gastric Cancer × Oxaliplatin × Clear all
NCT06764875 2026-05-12

A Phase â…¢ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

AstraZeneca

Phase 3 Recruiting
840 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

NCT07332533 2026-01-12

A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer

Shanghai JMT-Bio Inc.

Phase 2/3 Not yet recruiting
490 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

NCT06998771 2025-05-31

JSKN003 Combined Treatment of HER2-positive Gastric Cancer

Shanghai JMT-Bio Inc.

Phase 2 Not yet recruiting
153 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

NCT06439550 2024-06-03

Adjuvant Treatment With Serplulimab,Trastuzumab and SOX in the HER-2 Positive GC/GEJC

The First Affiliated Hospital of Zhengzhou University

Phase 2 Not yet recruiting
42 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡